Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

NIH funds HIV microbicide study

This article was originally published in The Tan Sheet

Executive Summary

A National Institutes of Health-funded study on the safety of its vaginal microbicide gel VivaGel (SPL7013) has begun, Starpharma Holdings announces July 10. The gel, intended to be used for the prevention of HIV and genital herpes, is being tested in 40 sexually active, HIV-negative women aged 18 to 24 for its safety, acceptability and ease of use at the University of South Florida in Tampa and the University of Puerto Rico in San Juan. Starpharma says it expects the product will ultimately be OTC, but in some markets it may be initially offered by prescription. In 2005 NIH funded a study on Indevus Pharmaceuticals' microbicide PRO 2000 (1"The Tan Sheet" Feb. 14, 2005, In Brief)...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS100711

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel